Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Abbvie Inc 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 USA

www.abbvie.com Employees: 55,000 P: 847-932-7900

Sector:

Medical

Description:

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

Key Statistics

Overview:

Market Capitalization, $K 383,080,704
Enterprise Value, $K 444,700,704
Shares Outstanding, K 1,767,385
Float, K 1,762,967
% Float 99.75%
Short Interest, K 18,076
Short Float 1.02%
Days to Cover 3.58
Short Volume Ratio 0.48
% of Insider Shareholders 0.25%
% of Institutional Shareholders 70.23%
Annual Net Income, $ 4,278 M
Last Quarter Sales, $ 15,776 M
Last Quarter Net Income, $ 186,000 K
EBIT, $ 9,034 M
EBITDA, $ 17,420 M
3-Year Return 44.90%
5-Year Return 95.52%
5-Year Revenue Growth 69.34%
5-Year Earnings Growth 13.20%
5-Year Dividend Growth 44.86%

Per-Share Information:

Most Recent Earnings 1.86 on 10/31/25
Next Earnings Date 02/04/26 [BMO]
Earnings Per Share ttm 9.45
EPS Growth vs. Prev Qtr -37.37%
EPS Growth vs. Prev Year -38.00%
Annual Dividend & Yield (Paid) 6.56 (3.03%)
Annual Dividend & Yield (Fwd) 6.56 (2.96%)
Most Recent Dividend 1.730 on 01/16/26
Next Ex-Dividends Date 01/16/26
Dividend Payable Date 02/17/26
Dividend Payout Ratio 68.08%

ABBV Ratios

Ratio
Price/Earnings ttm 23.48
Price/Earnings forward 15.38
Price/Earnings to Growth 0.91
Return-on-Equity % 3,216.47%
Return-on-Assets % 12.39%
Profit Margin % 7.59%
Debt/Equity -26.45
Price/Sales 6.44
Price/Cash Flow 14.86
Price/Book N/A
Book Value/Share -1.47
Interest Coverage 2.72
60-Month Beta 0.36

ABBV Dividends

Date Value
01/16/26 $1.7300
10/15/25 $1.6400
07/15/25 $1.6400
04/15/25 $1.6400
01/15/25 $1.6400
10/15/24 $1.5500
07/15/24 $1.5500
04/12/24 $1.5500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar